This bill establishes the 340B Drug Pricing Nondiscrimination Act, which aims to protect entities participating in the federal 340B drug pricing program from discriminatory practices by health insurers, pharmacy benefits managers (PBMs), manufacturers, and distributors. The legislation defines key terms like “340B drug” and “340B entity,” which refer to drugs and organizations participating in a federal program that provides reduced-price pharmaceuticals to certain healthcare providers. The bill prohibits various discriminatory practices, such as reimposing lower reimbursement rates on 340B entities, imposing different contract terms, interfering with patient choice of pharmacy, or requiring additional documentation for 340B drugs. It also prevents manufacturers and distributors from limiting access to 340B drug pricing and establishes potential civil fines between $100 and $10,000 for violations. The Attorney General is granted authority to enforce the provisions, and the law includes safeguards to ensure compliance does not conflict with federal regulations. The bill amends existing Oklahoma statutes to incorporate these new protections and will become effective on November 1, 2025, with the goal of ensuring fair treatment for healthcare providers participating in the 340B drug pricing program.